Therapy Trends Updates - Page 1

Learn More Non-Small Cell Lung Cancer (NSCLC): Update Bulletin #1 [November 2018]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US on a variety of recent events in the non-small cell lung cancer (NSCLC) market. KOLs provide...

Compare
Learn More Non-Alcoholic Steatohepatitis (NASH): Update Bulletin #2 [November 2018]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of non-alcoholic steatohepatitis (NASH). Topics covered include KOL views on Viking Therapeutics’ positive top-line...

Compare
Learn More Glioblastoma: Update Bulletin #3 [November 2018]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the glioblastoma multiforme (GBM) market. Within this update, KOLs...

Compare
Learn More Chronic Lymphocytic Leukaemia (CLL): Update Bulletin #1 [November 2018]

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the chronic lymphocytic leukaemia (CLL) market,...

Compare
Learn More Breast Cancer: Update Bulletin #2 [November 2018]

Gain new KOL insights on the latest events that have the potential to impact the treatment landscape of breast cancer (BC). Topics covered include expert opinions on: the FDA’s approval of Pfizer's Talzenna...

Compare
Learn More Bladder Cancer: Update Bulletin #1 [November 2018]

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the bladder cancer (BC) market. Within this update, KOLs provided their...

Compare
Learn More Targeted Therapies in Asthma: Update Bulletin # 3 [October 2018]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the severe asthma market. Within this...

Compare
Learn More Psoriasis: Update Bulletin # 1 [October 2018]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of psoriasis. Topics covered include; Bristol-Myers Squibb’s (BMS) initiation of two parallel Phase III studies comparing...

Compare
Learn More Ovarian Cancer: Update Bulletin # 2 [October 2018]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the ovarian cancer market. KOLs provided...

Compare
Learn More Future Innovation in Oncology: Update Bulletin # 1 [October 2018]

Topics covered include in this update bulletin include: Phase I data for novel RET inhibitor, LOXO-292 (Loxo) in patients with NSCLC and thyroid cancer; Jounce Therapeutics’ presentation of Phase I/II data for its...

Compare
Learn More Chronic Obstructive Pulmonary Disease (COPD): Update Bulletin #2 [October 2018]

This edition presents key opinion leader (KOL) views on recent developments in the chronic obstructive pulmonary disease (COPD) market. Topics covered include: the FDA Advisory Committee (AdCom) decision on GSK’s...

Compare
Learn More CAR-T therapies in Haematological Malignancy: Update Bulletin #2 [October 2018]

Gain new key opinion leader (KOL) insights on the latest events happening in the CAR-T treatment landscape.Topics covered include expert opinions on; the European Commission approval of Yescarta (Gilead/Kite) for adults...

Compare
Learn More Acute Myeloid Leukaemia: Update Bulletin #3 [October 2018]

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the acute myeloid leukaemia (AML) market...

Compare
Learn More Renal Cell Carcinoma: Update Bulletin #1 [September 2018]

This edition presents key opinion leader (KOL) views on recent developments in the Renal Cell Carcinoma (RCC) market. Topics covered include: Merck & Co. presenting data from the Phase II KEYNOTE-427 trial,...

Compare
Learn More Gastric Cancer: Update Bulletin #1 [September 2018]

This edition presents key opinion leader (KOL) views on recent developments in the treatment of gastric cancer. Topics covered include; Aslan Pharmaceuticals’ announcing that recruitment of 52 patients to the...

Compare
Learn More Multiple Myeloma: Update Bulletin #1 [September 2018]

This edition presents the views and insights from three world leading key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the multiple myeloma (MM) market, including: the extension...

Compare

Browse by